Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2006;107:1399-1410
© 2006 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Quiz
Right arrow CME Quiz Answers
Right arrow CME Quiz Answers
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhoola, S.
Right arrow Articles by Hoskins, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhoola, S.
Right arrow Articles by Hoskins, W. J.
Related Collections
Right arrow Gynecologic oncology
Right arrow Pathology

CLINICAL EXPERT SERIES

Diagnosis and Management of Epithelial Ovarian Cancer

Snehal Bhoola, MD and William J. Hoskins, MD

From the Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia.

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States. Although there has been a statistically significant improvement in 5-year survival, in 2005 more than 16,000 women were expected to die of this disease. To date, there is no reliable method to screen for ovarian cancer; therefore, the majority of cases are diagnosed with advanced disease. For early ovarian cancer, appropriate surgical staging and adjuvant chemotherapy for selected cases will result in survival rates of 90–95%. For advanced ovarian cancer, survival depends primarily on the success of the initial surgical procedure. Patients with complete cytoreduction to microscopic disease are often cured with adjuvant chemotherapy. There is growing evidence that these patients with microscopic residual disease are excellent candidates for intraperitoneal chemotherapy, and this mode of chemotherapy delivery may be their best opportunity for cure. Patients with optimal cytoreduction also may benefit from intraperitoneal chemotherapy, but cure is less likely. For patients with suboptimal cytoreduction, intravenous chemotherapy with a combination of carboplatin and paclitaxel is the current standard therapy. Most of these patients will experience recurrence of the cancer, with small chance of cure. Salvage chemotherapy is important in ovarian cancer because many patients respond to several salvage regimens. Because of the high response rate of ovarian cancer, even after relapse, it is probably better to consider 10-year survival as the ideal end point. Finally, new biologic agents, in combination with traditional surgery and chemotherapy, may result in further improvement in survival for patients with ovarian cancer.




This article has been cited by other articles:


Home page
 Hum ReprodHome page
J. W. Wright, T. Pejovic, J. Fanton, and R. L. Stouffer
Induction of proliferation in the primate ovarian surface epithelium in vivo
Hum. Reprod., January 1, 2008; 23(1): 129 - 138.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Yokoyama, G. Sedgewick, and S. Ramakrishnan
Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination
Cancer Res., November 15, 2007; 67(22): 10813 - 10822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-L. Chang, Y.-C. Tsai, L. He, T.-C. Wu, and C.-F. Hung
Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70
Cancer Res., October 15, 2007; 67(20): 10047 - 10057.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. D. Kirkpatrick, M. A. Brewer, and U. Utzinger
Endogenous Optical Biomarkers of Ovarian Cancer Evaluated with Multiphoton Microscopy
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2048 - 2057.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lassmann, Y. Shen, U. Jutting, P. Wiehle, A. Walch, G. Gitsch, A. Hasenburg, and M. Werner
Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy
Clin. Cancer Res., July 15, 2007; 13(14): 4083 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al.
A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples
Clin. Chem., June 1, 2007; 53(6): 1067 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. P. Bak, J. J. Walters, M. Takeya, J. R. Conejo-Garcia, and B. L. Berwin
Scavenger Receptor-A-Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression
Cancer Res., May 15, 2007; 67(10): 4783 - 4789.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Zhou, W. F. Han, L. E. Landree, J. N. Thupari, M. L. Pinn, T. Bililign, E. K. Kim, A. Vadlamudi, S. M. Medghalchi, R. El Meskini, et al.
Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells
Cancer Res., April 1, 2007; 67(7): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
M. R. Milam, A. K. Sood, S. King, R. L. Bassett Jr, K. H. Lu, B. M. Slomovitz, R. L. Coleman, and P. T. Ramirez
Supracervical Hysterectomy in Patients With Advanced Epithelial Ovarian Cancer
Obstet. Gynecol., March 1, 2007; 109(3): 641 - 646.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Obstetricians and Gynecologists.